Login / Signup

Hyper-Branched Cyclodextrin-Based Polymers as Anticoagulant Agents: In Vitro and In Vivo Studies.

Yousef Khazaei MonfaredMohammad MahmoudianGjylije HotiDaniel Mihai BisericaruFabrizio CalderaRoberta CavalliParvin Zakeri-MilaniAdrián MatencioFrancesco Trotta
Published in: Bioengineering (Basel, Switzerland) (2022)
This study tested the anticoagulant effect of cyclodextrin (CD) hyper-branched-based polymers (HBCD-Pols). These polymers were synthesized and tested for their coagulant characteristics in vitro and in vivo. Due to their polymeric structure and anionic nature, the polymers can chelate Ca 2+ , reducing the free quantity in blood. HBCD-Pol increased the blood clotting time, PT, and aPTT 3.5 times over the control, showing a better effect than even ethylenediaminetetraacetic acid (EDTA), as occured with recalcification time as well. A titration of HBCD-Pol and EDTA showed exciting differences in the ability to complex Ca 2+ between both materials. Before executing in vivo studies, a hemocompatibility study was carried out with less than 5% red blood cell hemolysis. The fibrinogen consumption and bleeding time were analyzed in vivo. The fibrinogen was considerably decreased in the presence of HBCD-Pol in a higher grade than EDTA, while the bleeding time was longer with HBCD-Pols. The results demonstrate that the anticoagulant effect of this HBCD-Pol opens novel therapy possibilities due to the possible transport of drugs in this carrier. This would give combinatorial effects and a potential novel anticoagulant therapy with HBCD-Pol per se.
Keyphrases
  • atrial fibrillation
  • red blood cell
  • venous thromboembolism
  • drug delivery
  • ionic liquid
  • risk assessment
  • mass spectrometry
  • climate change
  • case control
  • bone marrow
  • smoking cessation
  • human health